Table 1. Testing items and testing time points.

Project	Screening period	Neoadjuvant therapy period	Pre-surgical examination	Surgery	Adjuvant therapy and consolidated treatment period	Safety follow-up	Survival follow-up
Visit period	D-28~D-1	C1-C3	Surgery will be performed within 4–6 weeks of the preoperative therapy completion		C4-C17
		D1			D1
Sign informed consent	√
Demographic data collection	√
Tumour diagnosis	√
Past medical history	√
History of previous antineoplastic therapy	√
Physical examination	√		√
Vital signs	√	√	√		√
ECOG score	√	√	√		√	√
Complete blood count	√ (within 7 days)	√	√		√
Comprehensive metabolic panel	√ (within 7 days)	√	√		√
Coagulation function	√ (within 7 days)	√	√		√
Routine‌ urinalysis	√ (within 7 days)	√	√		√
Stool analysis	√ (within 7 days)	√	√		√
Thyroid function test	√ (within 7 days)	√	√		√
HIV/HBV/HCV virus testing	√
Pregnancy test	√ (within 7 days)
12-lead ECG	√ (within 7 days)	√	√		√
Echocardiography	√		√
Imaging (chest)	√		√ (within 7 days before surgery)		Assessment every four cycles
Imaging (parts of the body other than the chest)	√		√
Pathological response rate assessment				√ (Postoperative)
Peripheral blood sample acquisition	√		√(3 weeks after the last dose of neoadjuvant therapy to 7 days before surgery)	√ (3–4 weeks after surgery)	Acquisition every four cycles
Adverse events	√	√	√	√	√	√
Concomitant medications/concomitant therapies		√	√	√	√	√	√
Time to disease progression						√	√
Follow-up anti-tumour therapy						√	√